Oncotarget

Research Papers:

RNA sequencing analysis reveals protective role of kruppel-like factor 3 in colorectal cancer

Xiaohong Wang, Zhonghua Jiang, Yu Zhang, Xiang Wang, Li Liu and Zhining Fan _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:21984-21993. https://doi.org/10.18632/oncotarget.15766

Metrics: PDF 1378 views  |   HTML 2014 views  |   ?  


Abstract

Xiaohong Wang1,2,*, Zhonghua Jiang3,*, Yu Zhang2, Xiang Wang4, Li Liu4, Zhining Fan4

1Department of Digestive Endoscopy Center, Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China

2Department of Gastroenterology, Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, China

3Department of Gastroenterology, First People’s Hospital of Yancheng, Yancheng, Jiangsu Province, China

4Department of Digestive Endoscopy Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China

*These authors have contributed equally to this work

Correspondence to:

Zhining Fan, email: [email protected]

Keywords: colorectal cancer, KLF3, survival analysis

Received: November 02, 2016     Accepted: January 27, 2017     Published: February 28, 2017

ABSTRACT

The Kruppel-like factor (KLF) family of transcription factors plays an important role in embryonic formation and cancer progression. This study was performed to determine the clinical importance of the KLF family in colorectal cancer (CRC). In total, 361 patients with CRC from The Cancer Genome Atlas (TCGA) cohort were used to comprehensively study the role of the KLF family in CRC. The results were then further validated using an in-house cohort (n=194). Univariate and multivariate Cox proportional hazards models were used to assess the risk factors for survival. In the TCGA cohort, KLF3 (hazard ratio [HR], 0.501; 95% confidence interval [CI], 0.272–0.920; P=0.025), KLF14 (HR, 1.454; 95% CI, 1.059–1.995; P=0.020), and KLF17 (HR, 1.241; 95% CI, 1.030–1.494, P=0.023) were identified as potential biomarkers in the univariate analysis, but after Cox proportional hazards analysis, only KLF3 (HR, 0.473; 95% CI, 0.230–0.831; P=0.012) was shown to be independently predictive of overall survival in patients with CRC. This finding was validated in our in-house cohort, which demonstrated that KLF3 expression was an independent predictor of both overall survival (HR, 0.628; 95% CI, 0.342–0.922; P=0.035) and disease-free survival (HR, 0.421; 95% CI, 0.317–0.697, P=0.016). KLF3 expression was inversely correlated with the N stage (P=0.015) and lymphovascular invasion (P=0.020). Collectively, loss of KLF3 was correlated with aggressive phenotypes and poor survival outcomes. KLF3 might be a potential new predictor and therapeutic target for CRC. Further study is needed for a more detailed understanding of the role of KLF3 in CRC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15766